Search found 512 matches
- Sun Feb 21, 2021 11:12 pm
- Forum: ImetelChat
- Topic: Has Geron been straight with us?
- Replies: 1
- Views: 337
Has Geron been straight with us?
I am going to suggest to you that they have. A close look at slide 28 from the January presentation tells the story. Look at 2022. The investment line for commercialization in Europe takes a turn straight up yet "approval" waits for 2024 in LR MDS. This suggests to me that this is the likely timelin...
- Sun Feb 21, 2021 4:51 pm
- Forum: ImetelChat
- Topic: Over/Under on Full enrollment in MDS
- Replies: 1
- Views: 335
Re: Over/Under on Full enrollment in MDS
Hi Ryan, I like your prognostication. Under promise: enrollment by end of second quarter. Overdeliver: April 13. Considering 100 active sites need deliver 85 more enrollees and we are there. This might move top line date forward. Regards, bp
- Tue Feb 16, 2021 5:13 pm
- Forum: ImetelChat
- Topic: Possible unfortunate Blue Bird adverse side effect
- Replies: 2
- Views: 635
Possible unfortunate Blue Bird adverse side effect
2 MDS type side effects reported under investigation in Sickle Cell disease treatment. I am saddened to see a potential setback in the treatment of this terrible disease. https://www.marketwatch.com/story/bluebird-bio-shares-slide-34-after-company-suspends-trials-of-sickle-cell-disease-treatment-202...
- Mon Feb 15, 2021 5:54 pm
- Forum: ImetelChat
- Topic: This one’s for you too, Bill (cheng ho)
- Replies: 0
- Views: 336
- Sun Feb 14, 2021 6:45 pm
- Forum: ImetelChat
- Topic: What if? Musings.
- Replies: 7
- Views: 1211
Re: What if? Musings.
Continued: 8. Are there any other drugs in the clinic that have shown disease modification and if so how does Imetelstat stack up against them? Where do you see the greatest competitive threats? Constellation Pharma has a BET inhibitor that is being studied in MF and that they believe has disease mo...
- Sun Feb 14, 2021 6:42 pm
- Forum: ImetelChat
- Topic: What if? Musings.
- Replies: 7
- Views: 1211
Re: What if? Musings.
Gwickley, here is an example of the letter I wrote to Geron IR before the last shareholders meeting, with their responses. I posted this after I received it last year. The shareholders meeting really is a reasonable place to try to get information and potentially air grievances. At this point, given...
- Sat Feb 13, 2021 5:45 am
- Forum: ImetelChat
- Topic: From the recent EMEA meeting re Pediatric use
- Replies: 3
- Views: 456
Re: From the recent EMEA meeting re Pediatric use
Rccola, Thanks for getting this clarified. Sounds like no MA until top line data. A shame really when a conditional approval could be granted on the basis of the conditions fulfilled as noted previously.
- Fri Feb 12, 2021 7:40 pm
- Forum: ImetelChat
- Topic: From the recent EMEA meeting re Pediatric use
- Replies: 3
- Views: 456
From the recent EMEA meeting re Pediatric use
2.1.11. Imetelstat - Orphan - EMEA-001910-PIP03-20 Geron Corporation; Treatment of Acute Myeloid Leukemia (AML), Treatment of Myelodysplastic Syndromes (MDS), including Juvenile Myelomonocytic Leukemia (JMML) / Treatment of pediatric patients with relapsed or refractory AML or MDS, including JMML, f...
- Wed Feb 10, 2021 12:49 am
- Forum: ImetelChat
- Topic: What if? Musings.
- Replies: 7
- Views: 1211
Re: What if? Musings.
Gwickley, Pretty sure I have posted return letters here that I have received from Geron IR in response to my questions in the past. They have taken pains to respond and even followed up with clarifications after the last investor's meeting. I think it is worthwhile for you to compose a letter to the...
- Tue Feb 09, 2021 1:27 am
- Forum: ImetelChat
- Topic: What if? Musings.
- Replies: 7
- Views: 1211
Re: What if? Musings.
Pre COVID one could go to a shareholders meeting in May and ask in person. Some like Bridge did go and was quite satisfied with the reception and openness with which he was met. Nonetheless you can still submit questions for the shareholders meeting. In the past every question I have submitted was a...
- Sun Feb 07, 2021 2:59 am
- Forum: ImetelChat
- Topic: What if? Musings.
- Replies: 7
- Views: 1211
What if? Musings.
Greetings to all. A couple of recent thoughts. It's still unclear as to why there was no update at ASH re the MDS P II study. While there were of course no new patients added since the last EHA presentation, I was as I am sure you were curious to know what the status of the remaining patients in stu...
- Fri Feb 05, 2021 8:17 pm
- Forum: ImetelChat
- Topic: This one is for you, Bill
- Replies: 1
- Views: 536
Re: This one is for you, Bill
The question before the house is whether Geron has any IP in the 6-THIO-dg arena.
- Fri Feb 05, 2021 8:05 pm
- Forum: ImetelChat
- Topic: This one is for you, Bill
- Replies: 1
- Views: 536
- Wed Feb 03, 2021 3:08 am
- Forum: ImetelChat
- Topic: Bots trying to take down board
- Replies: 0
- Views: 537
Bots trying to take down board
To those trying to join the board, as I have noted previously (but those posts are probably buried), this board has been attacked by many bots (tens of thousands--I kid you not). If you are a potential legit poster please let me know on Geron YMB and I will sort through the bots posts and find you t...
- Sun Jan 31, 2021 7:36 pm
- Forum: ImetelChat
- Topic: Why does Geron's presentation show EU approval after FDA?
- Replies: 3
- Views: 784
Re: Why does Geron's presentation show EU approval after FDA?
From the EU re MA: "the benefit-risk balance of the medicine is positive". Check, just ask the KOLs "it is likely that the applicant will be able to provide comprehensive data post-authorisation"--two PIIIs in progress, Check "the medicine fulfils an unmet medical need"--huge transfusion requirement...
- Sun Jan 31, 2021 7:24 pm
- Forum: ImetelChat
- Topic: Why does Geron's presentation show EU approval after FDA?
- Replies: 3
- Views: 784
Why does Geron's presentation show EU approval after FDA?
That's a good question. Here is what is a little incongruent. 1. Geron's strongest data presentations have been at European conferences. 2. Geron's strongest voices have been predominated by European physicians (with the exclusion of Dr. Mascarenhas and Dr. Steensma from the US). 3. Orphan designati...
- Mon Jan 25, 2021 9:34 pm
- Forum: ImetelChat
- Topic: Nice review article
- Replies: 0
- Views: 579
Nice review article
https://journals.sagepub.com/doi/full/1 ... 0720986641
Only one agent reviewed here appears to be associated with disease modification. To clarify, disease modification=improved longevity, symptom control/regression etc.
Only one agent reviewed here appears to be associated with disease modification. To clarify, disease modification=improved longevity, symptom control/regression etc.
- Sun Jan 24, 2021 9:44 pm
- Forum: ImetelChat
- Topic: Relevant quote from the Holmstrom article
- Replies: 2
- Views: 1091
Re: Relevant quote from the Holmstrom article
Bill, not sure you are right about that, relevant proteins must be expressed as surface antigens. We have seen from these and previous article they do not appears to be. Thoughts?
- Tue Jan 19, 2021 8:04 pm
- Forum: ImetelChat
- Topic: Sailing between Scylla and Charybdis
- Replies: 1
- Views: 1282
Sailing between Scylla and Charybdis
Our Geron appears to be sailing successfully between the Scylla of FDA/EU/rest of the world regulation, and the Charybdis of competition (that would be a new drug class with no intraclass competition and new clearly defined treatment areas.). Thank you John and team. bp
- Mon Jan 18, 2021 9:03 pm
- Forum: ImetelChat
- Topic: Musings on Geron's current and future position
- Replies: 3
- Views: 1669
Re: Musings on Geron's current and future position
Thanks Bill, so far I see work on melanoma, lymphoma and solid tumors. Did I miss something in reference to MDS/MF? If so please elaborate. Also maybe speculate on a reasonable timeline. Thanks, bp